½ÃÀ庸°í¼­
»óǰÄÚµå
1595564

¼¼°èÀÇ Á¶·ç Ä¡·á ½ÃÀå : ¾àÁ¦ À¯Çü, Åõ¾à ÇüÅÂ, À¯Åë ä³Îº° ¿¹Ãø(2025-2030³â)

Premature Ejaculation Treatment Market by Drug Type (Dapoxetine, Phosphodiesterase Type 5 Inhibitors, Selective Serotonin Reuptake Inhibitors), Type, Dosage Form, Distribution Channel - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 180 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Á¶·çÄ¡·á½ÃÀåÀÇ 2023³â ½ÃÀå ±Ô¸ð´Â 35¾ï 2,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 38¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 9.80%·Î ¼ºÀåÇØ 2030³â¿¡´Â 67¾ï7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Á¶·ç(PE) Ä¡·á ½ÃÀå¿¡´Â ÀϹÝÀûÀÎ ³²¼º ¼º±â´É Àå¾Ö¸¦ °ü¸®Çϰųª ÇØ°áÇϱâÀ§ÇÑ ±¤¹üÀ§ÇÑ Á¦Ç°°ú Ä¡·á¹ýÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. °íÅë°ú ´ëÀΰü°è ¹®Á¦·Î À̾îÁú ¼ö ÀÖÀ¸¸ç, È¿°úÀûÀÎ °³ÀÔÀÇ Çʿ伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ½ÅüÀû ¹× ½É¸®Àû Ãø¸é ¸ðµÎ¸¦ Áö¿øÇÕ´Ï´Ù. ÁÖ¿ä ÃÖÁ¾ »ç¿ëÀÚ´Â °Ç°­ °ü¸® Á¦°ø¾÷ü¿Í ÇÔ²² ÀÓ»ó Á¶¾ð°ú ½ÃÆÇ ¿É¼ÇÀ» ¿ä±¸ÇÏ´Â ´Ù¾çÇÑ ¿¬·É´ëÀÇ ³²¼ºÀ» Æ÷ÇÔÇÕ´Ï´Ù. ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î´Â °Ç°­ ÀÇ½Ä Áõ°¡, ÀǾàǰ Áøº¸ ¹× ³²¼º ¼º °Ç°­¿¡ ´ëÇÑ °³¹æÀûÀÎ ³íÀǸ¦À§ÇÑ »çȸ·ÎÀÇ ÀüȯÀÌ Æ÷ÇԵ˴ϴÙ. °³¹ß ÀÌ´Ï¼ÅÆ¼ºê´Â Çõ½ÅÀûÀÎ Ä¡·á¹ý°ú °³ÀÎÈ­µÈ °Ç°­ °ü¸® ¼Ö·ç¼ÇÀ» °³¹ßÇϱâÀ§ÇÑ ºñ¿Á ÇÑ Åä¾çÀ» Á¦°øÇÕ´Ï´Ù. ƯÈ÷ ¿ø°Ý ÀÇ·á ¹× ÀüÀÚ»ó°Å·¡ Ç÷§ÆûÀÇ ÃâÇöÀº Ä¡·á¿¡ ´ëÇÑ ¾×¼¼½º¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ¿Í °°Àº Á¦¾àÀÌ °è¼Ó ¼ºÀåÀÇ °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ¾ç»ó¿¡¼­ ¸ÂÃãÇü ÀÇ·á ¹× ´õ ³ªÀº Áø´Ü ¹× Ä¡·á »ç¿ëÀÚ Á¤ÀǸ¦ À§ÇÑ ÀΰøÁö´ÉÀÇ ÅëÇÕÀÌ À¯¸Á½ÃµË´Ï´Ù. °æÀï ±¸µµ´Â ±âÁ¸ÀÇ ÁÖ¿ä Á¦¾à ȸ»ç¿Í ±âµ¿·ÂÀÖ´Â ½ÅÈï ±â¾÷ ¸ðµÎÀÇ È°µ¿À¸·Î Ȱ±âÂ÷°í °ßÁ¶ÇÏÁö¸¸ ¾ôÈù ½ÃÀå Æ¯¼ºÀ» ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. Ç÷§ÆûÀ» Ȱ¿ëÇÏ¿© ¼ÒºñÀÚ¿¡°Ô µµ´Þ À» È®´ëÇϰí Àå±âÀûÀÎ ¼ºÀåÀ» À¯ÁöÇϱâ À§ÇØ ¿¬±¸ °³¹ßÀ» À§ÇÑ °øµ¿ ¿¬±¸¿¡ ÀÓÇØ¾ß ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 35¾ï 2,000¸¸ ´Þ·¯
¿¹Ãø³â(2024) 38¾ï 6,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 67¾ï 7,000¸¸ ´Þ·¯
CAGR(%) 9.80%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â Á¶·ç Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Á¶·ç Ä¡·á ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ±×¸®°í »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñ ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖ¾î, ¼ÒºñÀÚ Çൿ°ú ±×°Í Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Á¶·ç¿¡ ´ëÇÑ °¢±¹ Á¤ºÎÀÇ ÀÎ½Ä Çâ»ó
    • Á¶·çÀÇ À¯º´·ü Áõ°¡
    • ¿ø°ÝÀÇ·á¿¡ ÀÇÇÑ Ä¡·áÀÇ °¡´É¼º
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Á¶·ç Ä¡·á¿Í °ü·ÃµÈ ºÎÀÛ¿ë
  • ½ÃÀå ±âȸ
    • Ä¡·áÁ¦ÀÇ ¿¬±¸°³¹ß Áõ°¡
    • »õ·Î¿î Áø´Ü Åø °³¹ßÀ» À§ÇÑ Àü·«Àû Á¦ÈÞ Áõ°¡
  • ½ÃÀåÀÇ °úÁ¦
    • ÀÇ·á Á¾»çÀÚÀÇ ºÎÁ·

Porter's Five Forces : Á¶·ç Ä¡·á ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ±â¹ýÀ» Á¦°øÇÕ´Ï´Ù. ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ´õ °­ÀÎÇÑ ½ÃÀå¿¡¼­ Æ÷Áö¼Å´×À» º¸Àå ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Á¶·ç Ä¡·á ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Á¶·ç Ä¡·á ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. ¸¦ Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹ÃøÇÒ ¼ö ÀÖ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡ µÇ¾ú½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : Á¶·ç Ä¡·á ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

Á¶·ç Ä¡·á ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ºÐ¸íÈ÷ ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õ´Â °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» Çϱâ À§ÇØ ÇÊ¿äÇÑ Áö°ßÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : Á¶·ç Ä¡·á ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Á¶·ç Ä¡·á ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ±âº» °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÐÇÒÇϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× ±ÇÀå : Á¶·ç Ä¡·á ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ ±æÀ» ±×¸³´Ï´Ù.

Á¶·ç Ä¡·á ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • Á¶·ç¿¡ ´ëÇÑ Á¤ºÎÀÇ ÀÇ½Ä Çâ»ó
      • Á¶·ç Áõ°¡
      • ¿ø°ÝÀÇ·á¿¡ ÀÇÇÑ Ä¡·áÀÇ °¡¿ë¼º
    • ¾ïÁ¦¿äÀÎ
      • Á¶·ç Ä¡·á¿Í °ü·ÃµÈ ºÎÀÛ¿ë
    • ±âȸ
      • Ä¡·áÁ¦ÀÇ ¿¬±¸°³¹ß Áõ°¡
      • »õ·Î¿î Áø´Ü Åø °³¹ßÀ» À§ÇÑ Àü·«Àû ¿¬°è °­È­
    • °úÁ¦
      • ÀÇ·á Á¾»çÀÚÀÇ ºÎÁ·
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå Á¶·ç Ä¡·á ½ÃÀå : ¾à À¯Çüº°

  • ´ÙÆø¼¼Æ¾
  • Æ÷½ºÆ÷µð¿¡½ºÅ×¶ó¾ÆÁ¦ 5Çü(PDE5) ¾ïÁ¦Á¦
  • ¼±ÅÃÀû ¼¼·ÎÅä´Ñ ÀçÈí¼ö ¾ïÁ¦Á¦
  • ±¹¼Ò ¸¶ÃëÁ¦
  • Á©Å¸³×

Á¦7Àå Á¶·ç Ä¡·á ½ÃÀå : À¯Çüº°

  • °æ±¸¿ä¹ý
    • ºñ ¼±ÅÃÀû ¼¼·ÎÅä´Ñ Àç Èí¼ö ¾ïÁ¦Á¦
    • ¼±ÅÃÀû ¼¼·ÎÅä´Ñ Àç Èí¼ö ¾ïÁ¦Á¦
  • ±¹¼Ò¿ä¹ý

Á¦8Àå Á¶·ç Ä¡·á ½ÃÀå : Á¦Çüº°

  • Á¤Á¦
  • ½ºÇÁ·¹ÀÌ

Á¦9Àå Á¶·ç Ä¡·á ½ÃÀå : À¯Åë ä³Îº°

  • º´¿ø
  • ¿Â¶óÀÎ ¾à±¹
  • ¼Ò¸Å ¾à±¹

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ Á¶·ç Ä¡·á ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á¶·ç Ä¡·á ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Á¶·ç Ä¡·á ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Ampio Pharmaceuticals, Inc.
  • Aytu BioPharma, Inc.
  • Bayer AG
  • Donga Pharmaceutical Co.,Ltd.
  • Eli Lilly and Company
  • Emcure Pharmaceuticals
  • Futura Medical PLC
  • GlaxoSmithKline PLC
  • Hetero Healthcare Limited
  • Menarini Group
  • NeuroHealing Pharmaceuticals Inc.
  • Pfizer Inc.
  • Veru Inc.
  • Wholesome Medtech Private Limited
  • zr pharma& GmbH
JHS 24.11.29

The Premature Ejaculation Treatment Market was valued at USD 3.52 billion in 2023, expected to reach USD 3.86 billion in 2024, and is projected to grow at a CAGR of 9.80%, to USD 6.77 billion by 2030.

The treatment market for premature ejaculation (PE) encompasses a wide array of products and therapies aimed at managing or resolving this common male sexual dysfunction. Defined as ejaculation that occurs sooner than desired, PE can lead to distress and interpersonal issues, underlining the necessity for effective interventions. Treatments range from oral pharmacological solutions like SSRIs to behavioral therapies and topical anesthetics, catering to both physical and psychological facets. The primary end-users include men across various age groups seeking clinical advice or over-the-counter options, alongside healthcare providers. Key growth drivers in this market involve increasing health awareness, advancements in pharmaceuticals, and the societal shift towards more open discussions on male sexual health. Technological advancements and R&D initiatives provide fertile ground for developing innovative treatment modalities and personalized healthcare solutions. In particular, the advent of telemedicine and e-commerce platforms has expanded access to treatments, creating new opportunities for market players. However, limitations such as stigma, lack of consumer awareness in less developed regions, and potential side effects of treatments continue to challenge growth. Regulatory hurdles and the need for extensive clinical trials can also delay the introduction of new drugs. In terms of innovation, personalized medicine and integrating artificial intelligence for better diagnosis and therapy customization hold promise. Exploration in non-invasive treatments and natural therapies offers potential innovation routes. The competitive landscape is pulsating with activities from both established pharmaceutical giants and nimble startups, reflecting a robust but intricate market nature. Companies eager to expand should leverage digital platforms to enhance consumer reach and engage in collaborations for R&D to sustain long-term growth. Addressing educational barriers and destigmatizing the condition through awareness campaigns can further enhance market penetration and consumer engagement.

KEY MARKET STATISTICS
Base Year [2023] USD 3.52 billion
Estimated Year [2024] USD 3.86 billion
Forecast Year [2030] USD 6.77 billion
CAGR (%) 9.80%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Premature Ejaculation Treatment Market

The Premature Ejaculation Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Raising governments awareness of premature ejaculation
    • Increasing prevalence of premature ejaculation
    • Availability of treatment through telehealth
  • Market Restraints
    • Side effects associated with the premature ejaculation treatment
  • Market Opportunities
    • Rising research & development of drugs for treatment
    • Increasing strategic collaborations for development of new diagnostic tools
  • Market Challenges
    • Shortage of medical professionals

Porter's Five Forces: A Strategic Tool for Navigating the Premature Ejaculation Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Premature Ejaculation Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Premature Ejaculation Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Premature Ejaculation Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Premature Ejaculation Treatment Market

A detailed market share analysis in the Premature Ejaculation Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Premature Ejaculation Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Premature Ejaculation Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Premature Ejaculation Treatment Market

A strategic analysis of the Premature Ejaculation Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Premature Ejaculation Treatment Market, highlighting leading vendors and their innovative profiles. These include Ampio Pharmaceuticals, Inc., Aytu BioPharma, Inc., Bayer AG, Donga Pharmaceutical Co.,Ltd., Eli Lilly and Company, Emcure Pharmaceuticals, Futura Medical PLC, GlaxoSmithKline PLC, Hetero Healthcare Limited, Menarini Group, NeuroHealing Pharmaceuticals Inc., Pfizer Inc., Veru Inc., Wholesome Medtech Private Limited, and zr pharma& GmbH.

Market Segmentation & Coverage

This research report categorizes the Premature Ejaculation Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Dapoxetine, Phosphodiesterase Type 5 (PDE5) Inhibitors, Selective Serotonin Reuptake Inhibitors, Topical Anesthetics, and Zertane.
  • Based on Type, market is studied across Oral Therapies and Topical Therapies. The Oral Therapies is further studied across Nonselective Serotonin Reuptake Inhibitor and Selective Serotonin Reuptake Inhibitor.
  • Based on Dosage Form, market is studied across Pills and Spray.
  • Based on Distribution Channel, market is studied across Hospitals, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Raising governments awareness of premature ejaculation
      • 5.1.1.2. Increasing prevalence of premature ejaculation
      • 5.1.1.3. Availability of treatment through telehealth
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with the premature ejaculation treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising research & development of drugs for treatment
      • 5.1.3.2. Increasing strategic collaborations for development of new diagnostic tools
    • 5.1.4. Challenges
      • 5.1.4.1. Shortage of medical professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Premature Ejaculation Treatment Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Dapoxetine
  • 6.3. Phosphodiesterase Type 5 (PDE5) Inhibitors
  • 6.4. Selective Serotonin Reuptake Inhibitors
  • 6.5. Topical Anesthetics
  • 6.6. Zertane

7. Premature Ejaculation Treatment Market, by Type

  • 7.1. Introduction
  • 7.2. Oral Therapies
    • 7.2.1. Nonselective Serotonin Reuptake Inhibitor
    • 7.2.2. Selective Serotonin Reuptake Inhibitor
  • 7.3. Topical Therapies

8. Premature Ejaculation Treatment Market, by Dosage Form

  • 8.1. Introduction
  • 8.2. Pills
  • 8.3. Spray

9. Premature Ejaculation Treatment Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Premature Ejaculation Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Premature Ejaculation Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Premature Ejaculation Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Ampio Pharmaceuticals, Inc.
  • 2. Aytu BioPharma, Inc.
  • 3. Bayer AG
  • 4. Donga Pharmaceutical Co.,Ltd.
  • 5. Eli Lilly and Company
  • 6. Emcure Pharmaceuticals
  • 7. Futura Medical PLC
  • 8. GlaxoSmithKline PLC
  • 9. Hetero Healthcare Limited
  • 10. Menarini Group
  • 11. NeuroHealing Pharmaceuticals Inc.
  • 12. Pfizer Inc.
  • 13. Veru Inc.
  • 14. Wholesome Medtech Private Limited
  • 15. zr pharma& GmbH
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦